regardless of positive clinical results, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering considerable resistance from managed care entities. The companies are frequently erecting barriers to access, such as high price requirements and approval processes that restrict consumer access. … Read More